CTO-GOG-3053

Please Note: This trial is no longer enrolling new participants

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053).

ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
Van Gorp T;Cibula D;Lv W;Backes F;Ortaç F;Hasegawa K;Lindemann K;Savarese A;Laenen A;Kim YM;Bodnar L;Barretina-Ginesta MP;Gilbert L;Pothuri B;Chen X;Flores MB;Levy T;Colombo N;Papadimitriou C;Buchanan T;Hanker LC;Eminowicz G;Rob L;Black D;Lichfield J;Lin G;Orlowski R;Keefe S;Lortholary A;Slomovitz B; ;
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy For Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors
Slomovitz BM;Cibula D;Lv W;Ortaç F;Hietanen S;Backes F;Kikuchi A;Lorusso D;Dańska-Bidzińska A;Samouëlian V;Barretina-Ginesta MP;Vulsteke C;Lai CH;Pothuri B;Zhang Y;Magallanes-Maciel M;Amit A;Guarneri V;Zagouri F;Bell M;Welz J;Eminowicz G;Hruda M;J Willmott L;Lichfield J;Wang W;Orlowski R;Aktan G;Gladieff L;Van Gorp T;